A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
收藏NIAID Data Ecosystem2026-03-06 收录
官方服务：
资源简介：
To evaluate the safety, tolerability, efficacy, and pharmacokinetics of MDX-1106 when administered to patients with advanced non-small cell lung cancer, colorectal cancer, malignant melanoma, clear cell renal cell cancer or hormone refractory prostate cancer
创建时间：
2006-08-15
